Rydapt and Zykadia

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of midostaurin and its active metabolites, which are all substrates of the isoenzyme. The increase in midostaurin concentrations may be particularly pronounced when CYP450 3A4 inhibitors are administered during the first week of midostaurin administration. When a single 50 mg dose of midostaurin was administered to healthy volunteers on day 6 of treatment with the potent CYP450 3A4 inhibitor ketoconazole (400 mg daily for 10 days), midostaurin systemic exposure (AUC) increased by 10.4-fold compared to administration with placebo. The AUC of the two active metabolites, CGP62221 and CGP52421, increased by 3.5- and 1.2-fold, respectively. When multiple doses of midostaurin (100 mg twice daily on days 1 and 2; 50 mg twice daily on days 3 to 28) were coadministered with itraconazole (100 mg twice daily on days 22 to 28 for 13 doses), the plasma concentrations on day 28 (Cmin) of midostaurin, CGP62221 and CGP52421 increased by 2.1-, 1.2- and 1.3-fold, respectively, compared to the corresponding day 21 Cmin concentrations with midostaurin alone. MANAGEMENT: Concomitant use of midostaurin with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, patients should be closely monitored for increased adverse reactions (e.g., nausea, vomiting, diarrhea, edema, hyperglycemia, hyperuricemia, QT prolongation, neutropenia, lymphopenia, thrombocytopenia, anemia), especially during the first week of consecutive midostaurin administration in patients with advanced systemic mastocytosis and during the first week of midostaurin administration in each cycle of chemotherapy in patients with acute myeloid leukemia. References "Product Information. Rydapt (midostaurin)." Novartis Pharmaceuticals, East Hanover, NJ. Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of midostaurin and its active metabolites, which are all substrates of the isoenzyme. The increase in midostaurin concentrations may be particularly pronounced when CYP450 3A4 inhibitors are administered during the first week of midostaurin administration. When a single 50 mg dose of midostaurin was administered to healthy volunteers on day 6 of treatment with the potent CYP450 3A4 inhibitor ketoconazole (400 mg daily for 10 days), midostaurin systemic exposure (AUC) increased by 10.4-fold compared to administration with placebo. The AUC of the two active metabolites, CGP62221 and CGP52421, increased by 3.5- and 1.2-fold, respectively. When multiple doses of midostaurin (100 mg twice daily on days 1 and 2; 50 mg twice daily on days 3 to 28) were coadministered with itraconazole (100 mg twice daily on days 22 to 28 for 13 doses), the plasma concentrations on day 28 (Cmin) of midostaurin, CGP62221 and CGP52421 increased by 2.1-, 1.2- and 1.3-fold, respectively, compared to the corresponding day 21 Cmin concentrations with midostaurin alone.

MANAGEMENT: Concomitant use of midostaurin with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, patients should be closely monitored for increased adverse reactions (e.g., nausea, vomiting, diarrhea, edema, hyperglycemia, hyperuricemia, QT prolongation, neutropenia, lymphopenia, thrombocytopenia, anemia), especially during the first week of consecutive midostaurin administration in patients with advanced systemic mastocytosis and during the first week of midostaurin administration in each cycle of chemotherapy in patients with acute myeloid leukemia.

Rydapt

Generic Name: midostaurin

Brand name: Rydapt

Synonyms: n.a.

What is Rydapt?

Zykadia

Generic Name: ceritinib

Brand name: Zykadia

Synonyms: n.a.

What is Zykadia?